Tianjin Chase Sun Pharmaceutical Co.,Ltd
Tianjin Chase Sun Pharmaceutical Co., Ltd., commonly referred to as Chase Sun, is a prominent player in the pharmaceutical industry, headquartered in Tianjin, China. Established in 1995, the company has made significant strides in the development and manufacturing of a diverse range of pharmaceutical products, including generic drugs and active pharmaceutical ingredients (APIs). With a strong operational presence across various regions in China and beyond, Chase Sun is recognised for its commitment to quality and innovation. The company’s core offerings, which include oncology and cardiovascular medications, stand out due to their rigorous research and development processes. Chase Sun has achieved notable market positioning, underscoring its reputation for excellence in the pharmaceutical sector. As a forward-thinking organisation, it continues to contribute to global health advancements while maintaining a focus on sustainable practices.
DitchCarbon Score
How does Tianjin Chase Sun Pharmaceutical Co.,Ltd's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Tianjin Chase Sun Pharmaceutical Co.,Ltd's score of 15 is higher than 80% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Tianjin Chase Sun Pharmaceutical Co.,Ltd's reported carbon emissions
In 2021, Tianjin Chase Sun Pharmaceutical Co., Ltd, headquartered in CN, reported significant carbon emissions totalling approximately 329,000,000 kg CO2e. This figure includes 39,385,000 kg CO2e from Scope 1 emissions, which are direct emissions from owned or controlled sources, and 57,184,000 kg CO2e from Scope 2 emissions, representing indirect emissions from the generation of purchased electricity, steam, heating, and cooling. The majority of their emissions, approximately 246,865,000 kg CO2e, fall under Scope 3, which encompasses all other indirect emissions that occur in the value chain. Currently, there are no publicly disclosed reduction targets or climate pledges from Tianjin Chase Sun Pharmaceutical Co., Ltd. This lack of specific commitments highlights a potential area for improvement in their climate strategy, especially as the pharmaceutical industry increasingly focuses on sustainability and carbon footprint reduction.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Get Started| 2021 | |
|---|---|
| Scope 1 | 39,385,000 |
| Scope 2 | 57,184,000 |
| Scope 3 | 246,865,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Tianjin Chase Sun Pharmaceutical Co.,Ltd is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
